Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
10/2000
10/05/2000WO2000057909A2 Attenuated dengue-2 virus vaccine
10/05/2000WO2000057908A2 Attenuated dengue-1 virus vaccine
10/05/2000WO2000057907A2 Multivalent dengue virus vaccine
10/05/2000WO2000057906A1 Human papillomavirus vaccine with disassembled and reassembled virus-like particles
10/05/2000WO2000057904A2 Attenuated dengue-3 virus vaccine
10/05/2000WO2000057903A2 48 human secreted proteins
10/05/2000WO2000057901A1 Modulation of vascular permeability by means of tie2 receptor activators
10/05/2000WO2000057890A1 Pulmonary delivery of protonated/acidified nucleic acids
10/05/2000WO2000057886A1 Dispersible macrolide compounds and method for the production thereof
10/05/2000WO2000057885A1 Pharmaceutical emulsions for retroviral protease inhibitors
10/05/2000WO2000057882A1 Concomitant drugs for preventing or treating infection with gram-positive bacteria
10/05/2000WO2000057878A1 Thiadiazolyl urea or thiourea derivatives for antiviral treatment
10/05/2000WO2000057870A2 Viral treatment
10/05/2000WO2000057869A2 Viral treatment
10/05/2000WO2000057868A2 Use of carbamamic acid derivatives for the treatment of viral infections
10/05/2000WO2000057866A2 Use of azalide antibiotics for the topical treatment or prevention of ocular infections
10/05/2000WO2000057854A2 Mechanically stable pharmaceutical presentation form containing liquid or semi-solid surface-active substances
10/05/2000WO2000057727A1 Nutritional compositions which contain slightly negatively charged, non-digestible polysaccharides and the use thereof for reducing transport through tight junctions
10/05/2000WO2000057705A1 In vitro induction of antigen-specific t-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens
10/05/2000WO2000057699A1 Oral anti-odor compositions
10/05/2000WO2000040217B1 Topical composition comprising n-acetylaldosamines or n-acetylamino acids
10/05/2000WO2000032228A3 Peptide-based vaccine for influenza
10/05/2000WO2000032178A3 Use of siburamine for the treatment of disorders of the central nervous system secondary to organic impairments
10/05/2000WO2000032171A3 Autoahesive oral transmucosal delivery dosage form
10/05/2000WO2000031280A3 Use of plus-strand synthesis elements in retroviral vectors
10/05/2000WO2000031127A3 Protein fragments for use in protein targeting
10/05/2000WO2000030625A3 Use of phosphonoformic acid derivatives for treating infections
10/05/2000WO2000028039A3 Identification of senv genotypes
10/05/2000WO2000027880A3 Rantes-derived peptides with anti-hiv activity
10/05/2000WO2000026243A3 Transmembrane 4 proteins
10/05/2000WO2000026225A3 Nucleosides with anti-hepatitis b virus activity
10/05/2000WO2000025811A3 Multicomponent meningococcal vaccine
10/05/2000DE19914817A1 New DNA for the multiple peptide resistance factor of Staphylococcus, useful for identifying agents that increase bacterial sensitivity to antimicrobial peptides
10/05/2000CA2383592A1 2384891 acids including open reading frames encoding polypeptides; orfx
10/05/2000CA2370441A1 50 human secreted proteins
10/05/2000CA2369458A1 47 human secreted proteins
10/05/2000CA2368951A1 50 human secreted proteins
10/05/2000CA2368927A1 45 human secreted proteins
10/05/2000CA2368881A1 50 human secreted proteins
10/05/2000CA2368880A1 Dispersible macrolide compounds and method for the production thereof
10/05/2000CA2368790A1 Attenuated dengue-3 virus vaccine
10/05/2000CA2368719A1 50 human secreted proteins
10/05/2000CA2368700A1 49 human secreted proteins
10/05/2000CA2368674A1 Multivalent dengue virus vaccine
10/05/2000CA2368673A1 Attenuated dengue-4 virus vaccine
10/05/2000CA2368647A1 Viral treatment
10/05/2000CA2368477A1 Polynucleotide and deduced amino acid sequences from stromal cells
10/05/2000CA2368469A1 50 human secreted proteins
10/05/2000CA2368467A1 50 human secreted proteins
10/05/2000CA2368442A1 48 human secreted proteins
10/05/2000CA2368302A1 49 human secreted proteins
10/05/2000CA2368281A1 50 human secreted proteins
10/05/2000CA2366305A1 Method for expressing proteins
10/05/2000CA2365728A1 Attenuated dengue-1 virus vaccine
10/05/2000CA2365415A1 Adaptation of virus to vertebrate cells
10/05/2000CA2365411A1 Attenuated dengue-2 virus vaccine
10/05/2000CA2361366A1 Novel compounds
10/04/2000EP1041149A2 Vaccine and antitoxin for treatment and prevention of C. difficile disease
10/04/2000EP1041075A1 Procedure for the preparation of dioxopenicillanic acid derivatives
10/04/2000EP1040200A1 Virulence-associated nucleic acid sequences and uses thereof
10/04/2000EP1040198A1 Recombinant rhabdovirus containing a heterologous fusion protein
10/04/2000EP1040191A2 Rantes mutants and therapeutic applications thereof
10/04/2000EP1040123A2 Human papillomavirus vaccine
10/04/2000EP1040112A1 Imidazonaphthyridines and their use in inducing cytokine biosynthesis
10/04/2000EP1040111A1 Integrin receptor antagonists
10/04/2000EP1040107A1 6-o-alkyl derivatives of erythronolide b
10/04/2000EP1040100A1 Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors
10/04/2000EP1040099A1 Azepine or larger medium ring derivatives and their use as pharmaceuticals
10/04/2000EP1040098A1 Integrin receptor antagonists
10/04/2000EP1040095A1 Cyclohexene carboxylates as neuraminidase inhibitors
10/04/2000EP1040094A1 Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
10/04/2000EP1039934A1 Gene therapy approaches to supply apolipoprotein a-i agonists and their use to treat dyslipidemic disorders
10/04/2000EP1039931A1 Multivalent recombinant antibodies for treating hrv infections
10/04/2000EP1039930A2 Adjuvanted vaccine formulation
10/04/2000EP1039928A1 Intranasal yellow fever vaccination
10/04/2000EP1039927A1 UGC (UPSTREAM GENE OF cdsA)
10/04/2000EP1039922A1 Improved interferon polymer conjugates
10/04/2000EP1039909A1 Method and composition of an oral preparation of itraconazole
10/04/2000EP1039904A1 Synergistic antimicrobial compositions
10/04/2000EP1039903A1 Il-8 receptor antagonists
10/04/2000EP1039893A1 Pharmaceutical compositions containing an omega-3 fatty acid oil
10/04/2000EP1039887A1 Methods for treatment of neuro- and nephro-disorders and therapeutic toxicities using aminothiol compounds
10/04/2000EP1019040A4 INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS
10/04/2000EP0766672B1 Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors
10/04/2000EP0705109B1 Adjuvants for vaccines against respiratory syncytial virus
10/04/2000CN1269013A Moleculars withch give out multiple active parts
10/04/2000CN1268980A Novel screening methods to identify agents that selectively inhibit hepatitis C virus replication
10/04/2000CN1268953A Ligand for herps simplex virus entry mediator and method of use
10/04/2000CN1268948A Optically pure camptothecin analogues, optically pure synthessi intermdidate and method for preparing same
10/04/2000CN1268947A Process to produce 4-hydroxy-2-oxo-pyrone derivates useful as protease inhibitors
10/04/2000CN1268944A 5,5-disubtituted-1,5-dihydro-4,1-benzoxazepin-2(3H)-ones useful as HIV reverse transcriptase
10/04/2000CN1057087C Substituted oxazine and thiazinozolidone anti microorganism agent
10/04/2000CN1056991C Medicine for treating newcastle disease
10/04/2000CN1056986C Chai-lian oral liquor
10/04/2000CN1056975C Compound women's moistening cleaner
10/03/2000US6127414 Antagonists of neuropeptide y and, in particular, in the treatment of cardiovascular diseases, e.g., vasoconstriction; hypotensive agents
10/03/2000US6127408 Thioether furan nitrone compounds; nervous system degenerative disorders, e.g. alzheimer's disease; analysis of free radicals by forming adducts; inhibit the forming of a beta(1-42) beta-pleated sheets and/or suppressing cytokines
10/03/2000US6127400 Salts of diamine pyrrolidine
10/03/2000US6127398 An enzyme inhibitor for the inhibition of phosphodiesterase typeiv or the production of tumor necrosis factor in a mammal; treating asthma, arthritis, bronchitis, chronic obstructive airway disease, psoriasis, allergic rhinitis
10/03/2000US6127376 Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants
1 ... 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 1446 1447 1448 1449 1450 1451 1452 1453 1454 1455 1456 ... 1798